Drug Trial Radar · NCT04107480
PRolaCT - Three Prolactinoma RCTs
Last checked: Nov 20, 2026Latest source record: Jul 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
880
Planned (sponsor's estimate)
Start
Jun 21, 2019
Primary completion
Mar 31, 2024
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Leiden University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate if endoscopic trans-sphenoidal prolactinoma resection as a first line treatment, or as an equally valid second line treatment after a short (4-6 months) or long (\>2 years) period of pretreatment with a dopamine agonist is superior to standard care for several outcome parameters. The main objectives are to investigate this for quality of life and remission rate. The secondary objectives are to investigate this for biochemical disease control, recurrence rates, clinical symptom control, tumor shrinkage on MRI, pituitary functioning, the occurrence of adverse reactions to treatment, disease burden, and cost-effectiveness.
Conditions
- Prolactinoma
- Prolactin-Producing Pituitary Tumor
Interventions
Endoscopic trans-sphenoidal adenoma resectionProcedure
Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group. Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice.
Dopamine AgonistsDrug
The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care. Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued. In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Health-Related Quality of LifeTime frame: 12 months after randomization/baseline
- Long-term remissionTime frame: 36 months after randomization/baseline
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Amsterdam University Medical Center, loc. AMC
Amsterdam-Zuidoost, North Holland, Netherlands · Not yet recruiting
Reinier de Graaf Gasthuis
Delft, South Holland, Netherlands · Not yet recruiting
Leiden University Medical Center
Leiden, South Holland, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.